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Abstract
 
Although hepatitis C virus (HCV) infection is very common, identification of patients during
acute infection is rare. Consequently, little is known about the immune response during this
critical stage of the disease. We analyzed the T lymphocyte response during and after acute re-
solving HCV infection in three persons, using interferon (IFN)-
 
g
 
 enzyme-linked immunospot
(ELISPOT) and human histocompatibility leukocyte antigen (HLA) peptide tetramer assays.
Acute infection was associated with a broadly directed T helper and cytotoxic T lymphocyte
(CTL) response, which persisted after resolution of clinical hepatitis and clearance of viremia.
At the earliest time point studied, highly activated CTL populations were observed that tempo-
rarily failed to secrete IFN-
 
g
 
, a “stunned” phenotype, from which they recovered as viremia
declined. In long-term HCV-seropositive persons, CTL responses were more common in per-
sons who had cleared viremia compared with those with persistent viremia, although the fre-
quencies of HCV-specific CTLs were lower than those found in persons during and after reso-
lution of acute HCV infection. These studies demonstrate a strong and persistent CTL response
in resolving acute HCV infection, and provide rationale to explore immune augmentation as a
therapeutic intervention in chronic HCV infection.
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Introduction
 
Hepatitis C virus (HCV)
 
1
 
 is a major public health problem,
affecting an estimated 170 million people worldwide and
more than 10% of the population in some countries (1).
The virus persists in most cases, and can go on to cause he-
patic inflammation, fibrosis, and ultimately death through
liver failure or hepatocellular carcinoma. The mechanisms
that cause both viral persistence and hepatic pathology are
unknown. It is known that immune responses are present
during chronic infection, and it has been suggested that
these are present at too low a level to control or eliminate
the virus yet sufficient to sustain low-grade liver inflamma-
tion (2–4). Analysis of these antiviral responses has often
been hampered by the requirement for extensive in vitro
culture of lymphocytes before detection, which renders
quantification difficult, and also because studies have been
largely confined to patients with established disease (2–10).
Although HCV infection is very common, it rarely pre-
sents acutely, as the disease is usually not accompanied by
overt jaundice and patients rarely seek medical attention.
Consequently, little is known about the specificity and ki-
netics of the immune response during this period. In other
well-studied persistent viral infections, the immunological
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Abbreviations used in this paper: 
 
aa, amino acid(s); ALT, alanine transam-
inase; B-LCL, B lymphoblastoid cell line; CCR, CC chemokine recep-
tor; ELISPOT, enzyme-linked immunospot; HCV, hepatitis C virus;
PerCP, peridinine chlorophyll protein; RT, reverse transcription; SOD,
superoxide dismutase. 
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events that occur during the earliest stages of infection are
crucial in determining the eventual outcome of the disease
(11–14). For example, failure to mount an effective antivi-
ral cellular immune response against HIV may be followed
by rapidly progressive disease (15, 16). Antiviral CTLs are
able to migrate into infected tissues, recognize infected cells
presenting viral peptides in association with MHC class I,
and suppress viral replication through a combination of cy-
tolysis and secretion of antiviral cytokines, especially IFN-
 
g
 
(17–20). To maintain such activity, they require support
from antiviral T helper cells (21, 22). During acute HCV
infection, little is known about how the T cell responses,
particularly CTL responses, evolve over time and how such
activity relates to the course of clinical hepatitis (23–25).
Detailed information on this stage of infection is clearly of
value both in understanding the pathogenesis of the disease
and potentially in vaccine design.
This study has assessed both the breadth of the T cell re-
sponse using in vitro culture techniques to define CTL
epitopes, and also the phenotype and function of individual
responses using enzyme-linked immunospot (ELISPOT)
and MHC class I–peptide tetramers, combined with intra-
cellular cytokine staining. These techniques allow sensitive
and specific quantification of antigen-specific T cells, and
together have revealed in other infections hitherto unde-
tectable populations of antigen-specific cells that are unable
to proliferate or secrete IFN-
 
g
 
 in tissue culture (22, 26–
28). We have characterized CTL responses in three patients
undergoing or immediately after acute hepatitis and com-
pared them with those found in persons many years after
HCV exposure.
 
Materials and Methods
 
Study Subjects and Samples.
 
All subjects were HLA typed by
PCR or conventional serology and screened for the presence of
HCV antibodies by ELISA (Abbot Laboratories). Subject 1
 
 
 
was a
42-yr-old current intravenous drug user who had recently shared
needles with a friend who was known to be HCV-seropositive
and HIV-seropositive. He presented with an acute onset of mal-
aise and jaundice. Initial laboratory investigations included ala-
nine transaminase (ALT) 1073 U/liter, total bilirubin 8.6 mg/dl,
anti-HCV–positive by ELISA, HCV RNA–positive, and HIV
RNA–negative. Other causes of acute hepatitis, such as drug tox-
icity and other forms of viral hepatitis, were ruled out on history
and serologic testing. A clinical diagnosis of acute HCV infection
was made, and no specific pharmacologic treatment was advised.
By 6 wk, his symptoms had resolved and his ALT had normal-
ized. PCR for HCV RNA became negative at 4 wk and re-
mained so during the 1 yr of follow-up. Subject 2 was a 67-yr-
old woman who presented 5 wk after cosmetic surgery with
symptoms of acute hepatitis. Her ALT was 703 U/liter, and she
was seronegative for hepatitis A and B viruses but antibody- and
PCR-positive for HCV. 4 wk later, she was HCV reverse tran-
scription (RT)-PCR–negative, and ALT had normalized. She re-
mained HCV RNA PCR–negative with normal ALT during 2
yr of follow-up. Subject 3 was a 32-yr-old female partner of an
HCV-infected intravenous drug user. She presented to the hospi-
tal with signs of acute hepatitis and ALT of 882 U/liter. She was
seronegative for hepatitis A and B and HIV, and positive for
 
HCV antibodies and RNA. 10 wk later, she was HCV RNA
PCR–negative and remained so for the duration of follow-up of
2 yr, during which time her ALT remained in the normal range.
Long-term follow-up subjects who were HCV antibody– and
HCV RNA–positive or –negative were recruited from Oxford
(Table I). This group consisted of 36 HLA-A2
 
1
 
 subjects who had
been HCV-seropositive for at least 2 yr before analysis (mean 16,
range 2–30 yr). 19 subjects were persistently RNA-positive, and
17 subjects were persistently PCR-negative (at least 3 indepen-
dent tests). PBMCs were obtained from patients by centrifuga-
tion over Lymphoprep (Nycomed Pharma SA), followed by
washing in RPMI 1640 (Sigma Chemical Co.) and 10% FCS.
PBMCs were frozen immediately and stored in liquid nitrogen
until ELISPOT and tetramer analyses were performed. In most
cases, analyses of frozen sequential samples by the different assays
were performed simultaneously after thawing.
 
Synthesis of HCV-derived Peptides.
 
Peptides corresponding to
the amino acid (aa) sequences of the HCV-1 strain were synthe-
sized as free acids by Cambridge Research Biochemicals or Chi-
ron Mimotopes using the Fmoc method. Peptides were 20 aa in
length, overlapping adjacent peptides by 10 aa. Fine mapping was
achieved using additional smaller peptides in free acid form, which
were synthesized on an automated peptide synthesizer (model
432A; Applied Biosystems, Inc.). Peptides (9-aa length) for tet-
rameric complexes were purchased from Research Genetics.
 
Identification of Virus-specific CTL Responses.
 
Lymphocytes were
expanded with a single round of antigen-specific stimulation, us-
ing a protocol modified from Lubaki et al. (29). Stimulator cells
that presented all potential HCV antigens in the context of autol-
ogous HLA alleles were prepared by infecting 4 
 
3
 
 10
 
6
 
 autologous
EBV-transformed B lymphoblastoid cell lines (B-LCLs) with the
vaccinia HCV recombinant viruses (see below) at a multiplicity of
infection of 5–10 for 18 h. The vaccinia viruses were then inacti-
vated by resuspending the stimulator cells in 5 ml of a 10 
 
m
 
g/ml
psoralen solution (4
 
9
 
-aminomethyl-4
 
9
 
,5
 
9
 
-8-trimethylpsoralen hy-
drochloride; HRI Associates) and then exposing the cells to long
UV light (8-W bulb, 350–400-nm light; Fisher Scientific) for 5
min, followed by 100-Gy irradiation. PBMCs (4–6 
 
3
 
 10
 
6
 
 cells)
were stimulated with the stimulator B-LCL (2 
 
3
 
 10
 
6
 
 cells in-
fected with HCV-H 1–966 and 2 
 
3
 
 10
 
6
 
 cells infected with
HCV-H 827–3011 [30], a gift of Dr. C. Rice, Washington Uni-
versity School of Medicine, St. Louis, MO) and allogeneic irradi-
ated (30-Gy) PBMC feeder cells (20 
 
3
 
 10
 
6
 
) in 20 ml R-10 me-
dium (RPMI 1640 medium supplemented with 10% FCS, 2 mM
 
l
 
-glutamine, 50 U/ml penicillin, and 50 
 
m
 
g/ml streptomycin)
and incubated at 37
 
8
 
C with 5% CO
 
2
 
. R-10 medium containing
rIL-2 (50 U/ml) was added on day 3. On day 14, clones were de-
rived from bulk-expanded cells by subculturing in 96-well plates
at limiting dilution (25, 10, 5, and 3 cells per well) with 2 
 
3 
 
10
 
4
 
allogeneic irradiated (30 Gy) PBMC feeder cells in 200 
 
m
 
l R-10
medium with the CD3-specific mAb 12F6 (0.1 
 
m
 
g/ml; a gift of
Dr. J. Wong, Massachusetts General Hospital) and rIL-2 (100
U/ml). Developing cells were restimulated in 24-well plates with
irradiated (30 Gy) allogeneic feeder cells (1 
 
3
 
 10
 
5
 
 cells/well), 12F6
(0.1 
 
m
 
g/ml), and rIL-2 (100 U/ml) in R-10 medium.
 
 
 
Specificity
of unselected clones was then identified by analysis of lytic ac-
tivity against autologous B-LCLs infected with recombinant
vaccinia vectors expressing aa 1–339 (9A), 1–966 (HCV-H),
339–906 (1H), 364–1619 (NNRd), 827–3011 (HCV-H), 1590–
2050 (NS4), 2005–2396 (NS5A), 2396–3011 (NS5B), and vvLacZ
(control vaccinia vector expressing the 
 
Escherichia coli
 
 
 
b
 
-galactosi-
dase gene; a gift of Dr. M. Houghton, Chiron Corp., Emeryville,
CA). HCV-specific clones (defined as clones having 
 
.
 
20% spe- 
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Table I.
 
Characteristics of HCV-seropositive Subjects
 
Patient no. Age Sex ALT RT-PCR Liver histology
 
*
 
Treatment
 
‡
 
Minimal duration
of PCR
 
2
 
 status
 
§
 
Tetramer positivity
 
i
 
yr U/liter mo
 
1
 
¶
 
42 M 23 Neg Not done None 15 2/4
2
 
¶
 
67 F 19 Neg Not done None 14 2/3
3
 
¶
 
32 F 12 Neg Not done None 23 2/3
4 32 F 29 Neg Not done None 24 2/4
5 45 F 13 Neg Not done None 58 2/4
6 26 M 12 Neg Not done None 17 2/4
7 37 F 11 Neg CAH/F 2 24 2/3
8 38 F 20 Neg CAH/F 2 7 2/4
9 40 F 6 Neg CAH 2 24 2/3
10 55 F 12 Neg Not done None 18 1/3
11 35 M 27 Neg Not done None 10 1/3
12 41 F 7 Neg Not done None 72 1/4
13 50 M 32 Neg Not done None 20 1/4
14 33 F 15 Neg CAH/F 2 1 1/3
15 40 F 10 Neg Not done 1 48 1/4
16 40 M 15 Neg Not done None 95 0/3
17 35 F 35 Neg Not done None 38 0/3
18 45 F 13 Neg CAH 2 21 0/3
19 38 F 42 Neg CAH/F 2 1 0/3
20 34 F 10 Neg CAH 2 5 0/4
Mean 40 18
Patient no. Age Sex ALT RT-PCR Liver histology Treatment Time after treatment Tetramer positivity
 
yr U/liter mo
 
21 46 M 52 Pos CAH/F 2 24 3/4
22 44 F 24 Pos CAH None – 1/4
23 69 F 40 Pos CAH None – 1/4
24 36 M 37 Pos CAH 1 68 1/3
25 56 F 17 Pos CAH/F 2 30 1/3
26 50 F 35 Pos CAH/F None – 1/4
27 39 M 29 Pos CAH/F 2 20 1/4
28 54 M 151 Pos CAH/F None – 1/3
29 36 M 148 Pos CAH/F 2 4 1/4
30 40 M 17 Pos CAH None – 0/4
31 49 M 372 Pos CAH/F 2 15 0/4
32 38 F 38 Pos Not done None – 0/4
33 46 M 42 Pos CAH None – 0/3
34 60 F 48 Pos CAH 2 9 0/3
35 50 M 155 Pos CAH/F 2 15 0/3
36 48 M 110 Pos CAH/F 2 1 0/3
37 37 M 51 Pos CAH None – 0/3
38 56 M 45 Pos CAH None – 0/3
39 34 M 28 Pos CAH None – 0/4
Mean 47 76
 
*
 
Liver histology before treatment: CAH, chronic active hepatitis; CAH/F, chronic active hepatitis with fibrosis.
 
‡
 
Treatment: 1, IFN-
 
a
 
 alone; 2, IFN-
 
a
 
 and ribavarin.
 
§
 
Minimal duration of HCV RT-PCR–negative status at time of tetramer analysis.
 
i
 
No. of tetramers giving positive staining results/total no. of tetramers (not all patients were tested with the NS5B 2594 tetramer).
 
¶
 
Patients with acute hepatitis C. ALT and PCR results are from the last time point of follow-up (
 
.
 
50 wk). 
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cific lysis and 
 
,
 
10% background lysis) were maintained in long-
term culture in T-25 flasks by restimulating 2–4 
 
3
 
 10
 
6
 
 lympho-
cytes every 3–4 wk with 20 
 
3
 
 10
 
6
 
 irradiated (30 Gy) allogeneic
PBMC feeders, 0.1 
 
m
 
g/ml 12F6, and 50 U/ml rIL-2 in 20 ml
R-10 medium. HLA restriction of individual clones was deter-
mined by using partially HLA-matched B-LCLs. The fine speci-
ficity of the clones was determined using peptides 20 aa in length,
overlapping by 10 aa, and subsequently truncated peptides. Opti-
mal epitopes were defined as the smallest peptide that sensitized
target cells for maximal lysis in a cytotoxicity assay at the lowest
peptide concentration.
 
 
 
Cytotoxicity assays using 
 
51
 
Cr-labeled
B-LCLs as targets were performed as described previously (2, 8).
Longitudinal quantification of activity against peptide epitopes
was then analyzed directly on PBMCs using optimal epitopes in
an IFN-
 
g
 
 ELISPOT analysis as described below.
 
Quantification of T Cell Responses Using IFN-
 
g
 
 ELISPOT Assay.
 
Cryopreserved PBMCs were thawed and incubated at 37
 
8
 
C
overnight in R-10 medium. 96-well nitrocellulose plates (Milli-
pore) were coated with 2.5 
 
m
 
g/ml recombinant human anti–
IFN-
 
g
 
 antibody (Endogen) in a carbonate/bicarbonate buffer
(pH 9.6) overnight at 4
 
8
 
C. Autologous B-LCLs were infected
with different recombinant HCV-vaccinia virus vectors over-
night, washed, and 1 
 
3
 
 10
 
5
 
 cells per well were used as antigen-
presenting cells. PBMCs were added at 1 
 
3
 
 10
 
5
 
, 0.5 
 
3
 
 10
 
5
 
, and
0.25 
 
3
 
 10
 
5
 
 cells per well in duplicates. For detection of peptide-
specific CD8
 
1
 
 T cells, synthetic peptides (5 
 
m
 
g/ml) correspond-
ing to defined optimal epitopes were added to PBMCs. For T
helper cell assays, PBMCs were incubated with soluble protein
antigens (10 
 
m
 
g/ml) in 96-well U-bottomed plates overnight and
then transferred directly into the ELISPOT plate. The following
protein antigens were used: HCV-1 C22-3 (core, aa 2–120),
C33c (NS3, aa 1192–1457), C100 (NS4, aa 1569–1931), and
NS5 (aa 2054–2995) expressed as COOH-terminal fusion pro-
teins with superoxide dismutase (SOD) in yeast or 
 
E. coli
 
 (pro-
vided by Chiron Corp.). Recombinant SOD was used as control
antigen. The ELISPOT method using recombinant proteins was
specific for CD4
 
1
 
 T lymphocytes as determined previously with
other HCV blood donors using CD8
 
1
 
 or CD4
 
1
 
 lymphocyte-
depleting antibodies. After incubation at 37
 
8
 
C for 20–24 h, the
plates were washed, labeled with 0.25 mg/ml biotin-labeled anti–
human IFN-
 
g
 
 (Endogen), and developed by incubating with
streptavidin–alkaline phosphatase (Bio-Rad) followed by incubat-
ing with BCIP/NBT (Bio-Rad) in Tris buffer (pH 9.5). The re-
action was stopped by washing with tap water and allowed to dry
before counting the spots at a magnification of 40, with a dissec-
tion microscope. All wells with 10–150 spots were considered
evaluable, and estimates of cell frequencies were obtained by lin-
ear regression analysis.
 
Tetrameric MHC Class I–Peptide Complexes.
 
Tetrameric pep-
tide–MHC class I complexes were made as described previously
(31). In brief, recombinant human 
 
b
 
2-microglobulin and the ex-
tracellular portion of the MHC class I heavy chain A
 
*
 
0201 con-
taining the BirA recognition sequence in frame at its COOH ter-
minus were expressed in 
 
E
 
.
 
 coli 
 
as insoluble aggregates that
formed inclusion bodies. Purified inclusion bodies were solubi-
lized in urea and monomeric HLA class I complexes refolded
around peptide by dilution of denaturing conditions. The follow-
ing peptides were used: HCV NS3 1073–1081 (CINGVCWTV),
NS3 1406–1415 (KLVALGINAV), NS4B 1807–1816 (LLF-
NILGGWV), NS5B 2594–2602 (ALYDVVTKL) (2, 5, 32), and
EBV lytic protein BMLF1 (GLCTLVAML) (33). After buffer ex-
change, a specific lysine residue in the heavy chain COOH-ter-
minal tag was biotinylated with BirA enzyme (Avidity). Mono-
 
meric complexes were purified by gel filtration and anion
exchange chromatography. Tetrameric arrays of biotinylated pep-
tide–MHC class I complexes were formed by the addition of PE-
labeled avidin (Extravidin; Sigma Chemical Co.) at a molar ratio
of 4:1. For confirmation of specificity, tetramer staining was per-
formed on HLA-A2–restricted HCV-specific CTL lines or clones
derived from infected patients as described previously (5, 8, 34;
data not shown). Staining of PBMCs from healthy HCV-seroneg-
ative individuals and of cloned CTLs diluted in PBMCs from
healthy individuals established that the approximate limit of de-
tection with tetramers was at 0.02% of CD8
 
1
 
 lymphocytes (data
not shown). FACS
 
®
 
 staining results of PBMCs were only consid-
ered specific when the tetramer-positive cells formed a cluster
distinct from the tetramer-negative CD8
 
1
 
 lymphocytes. Staining
of uninfected controls was routinely 
 
,
 
0.02% of CD8
 
1
 
 lym-
phocytes. In some instances, results were confirmed by peptide
pulsing of PBMCs and staining after 8 d, which led to a peptide-
specific increase in numbers of tetramer-positive cells in HCV-
seropositive but not control subjects (not shown).
 
Flow Cytometry. For tetramer staining, thawed PBMCs were
washed three times in RPMI 1640 and 10% FCS and stained
with tetrameric complexes and antibodies. The following mAbs
were used: anti-CD8–TriColor (Caltag Laboratories), anti-CD8–
peridinine chlorophyll protein (PerCP; Becton Dickinson Im-
munocytometry Systems), anti-CD38–allophycocyanin (Becton
Dickinson), anti–human MHC class II–FITC (HLA-DR, -DP,
and -DQ; Dako), and anti–CC chemokine receptor (CCR)5–
FITC (PharMingen). 106 PBMCs were first incubated with tet-
rameric complexes for 20 min at 378C, then the antibodies were
added and incubated for an additional 20 min on ice. The cells
were washed with PBS/2% FCS and fixed with 0.5% formalin/
PBS. Samples were analyzed on a FACSCalibur™ flow cytome-
ter, and the data were analyzed using CELLQuest™ software
(Becton Dickinson). For intracellular IFN-g staining, thawed and
washed PBMCs were incubated at 378C for a total of 6 h in the
presence of PMA (50 ng/ml) and ionomycin (500 ng/ml).
Brefeldin A (10 mg/ml) was added for the last 4 h of incubation.
After washing with PBS/2% FCS, the cells were stained with tet-
ramers for 20 min at 378C and again washed in PBS/2% FCS.
The cells were fixed in 4% (wt/vol) paraformaldehyde/PBS for
10 min on ice and then permeabilized using PBS containing 2%
FCS, 0.1% (wt/vol) sodium azide, and 0.1% (wt/vol) saponin
(permeabilization buffer; 10 min on ice). Permeabilized cells
were stained with anti-CD8–PerCP and anti–IFN-g–FITC or
FITC-conjugated isotype control antibody (Becton Dickinson).
The stained cells were washed twice in permeabilization buffer
and once in PBS/2% FCS, then fixed in 0.5% formalin/PBS, and
analyzed by flow cytometry. For peptide-induced upregulation of
CD69, thawed and washed PBMCs were incubated with 1 mM
peptide for 4 h and then washed with PBS/2% FCS. The cells
were stained with tetramers for 30 min at 378C, followed by an
incubation with FITC-conjugated anti-CD69 antibodies (Becton
Dickinson) and PerCP-conjugated anti-CD8 antibodies for 30
min on ice. After washing with PBS/2% FCS, the cells were
fixed and analyzed by flow cytometry.
Results
Analysis of the Breadth of the HCV-specific CD81 Lympho-
cyte Response in a Subject with Resolving Acute HCV Infec-
tion. A 42-yr-old intravenous drug user presented to the
hospital with acute HCV infection, characterized by ele-1503 Lechner et al.
vated ALT and HCV RNA positivity. ALT subsequently
normalized, and HCV RNA became negative. Blood sam-
ples were available from this subject during and after acute
illness such that the development of HCV-specific T cell
responses during a successful elimination of the virus could
be studied in detail. In an initial set of experiments, the
CTL epitopes recognized were identified and characterized
by in vitro expansion and cloning of PBMCs from a week
4 blood sample after stimulation with autologous B-LCLs
infected with recombinant HCV-vaccinia viruses (see Ma-
terials and Methods). 120 clones were raised and screened
for CTL recognition of autologous B-LCLs infected with
recombinant HCV-vaccinia viruses. All HCV-specific
CTL clones were further characterized using a panel of
overlapping peptides representing the expressed gene prod-
ucts of HCV-1. A total of 80 HCV-specific CTL clones
were generated and found to recognize one of 8 epitopes: 2
restricted by HLA-A2 (NS3 1073–1081 and NS5B 2594–
2602), 1 by HLA-B37 (NS4 1966–1976), and 5 by HLA-
A25 (NS2 832–841, NS4 1744–1754, NS4 1758–1766,
NS4 2225–2233, and NS5A 2225–2233). This method was
repeated for PBMCs from weeks 0, 10, and 24, yielding
clones of the same specificities, but no additional epitopes
were identified.
Except for the HLA-A2–restricted epitope NS3 1073, all
defined epitopes recognized by subject 1 had not been de-
scribed previously. Fig. 1 demonstrates the cytolytic activ-
ity of individual clones using target cells pulsed with the
optimal epitopes. The newly identified HLA-A2–restricted
NS5B 2594 response targets a peptide conforming to the
defined HLA-A2 motif, with a leucine at the COOH ter-
minus and at position 2 (35). The A25-restricted responses
all have a motif similar to that described in a conserved
peptide from HIV p24 gag (36), which includes a tryp-
tophan at the COOH terminus. Together, these data indi-
cate that the CTL response in this subsequently controlled
infection was simultaneously targeted at eight different
epitopes.
Longitudinal Quantification of the CTL Response in Resolv-
ing Acute HCV Infection. The availability of longitudinal
samples in subject 1 allowed for the detailed quantification
of CTL responses over the course of resolving acute hepati-
tis. Comparison was made using two separate techniques.
Initially, CTL responses to naturally processed viral pro-
teins expressed by recombinant HCV-vaccinia viruses were
determined using an IFN-g ELISPOT assay. This assay
confirmed the multispecificity of the response, and demon-
strated that responses peaked between weeks 4 and 10, at a
time when ALT levels had already normalized and no viral
RNA was detectable in blood (Fig. 2 A). These results
were confirmed using a second IFN-g ELISPOT assay, in
which PBMCs were stimulated with the individual optimal
peptides as identified using cloned CTLs (Fig. 2 B). Both
assays showed that the magnitude of the overall response
was maximal at week 10 after onset of jaundice. Relative
responses to individual proteins were similar with both
ELISPOT assays. In the peptide ELISPOT, the HLA-A25–
restricted response to NS4 1744 was maximal at the earliest
time point tested (Fig. 2 B), although the overall response
to NS4 (containing another two identified epitopes)
peaked between weeks 5 and 10, similar to the other pro-
teins (Fig. 2 A). Assuming that 10% of PBMCs are CD81
lymphocytes, the total number of IFN-g–producing cells
was estimated to represent z6% of CD81 lymphocytes at
the peak of the response. These results indicate that the
magnitude of the HCV-specific IFN-g2producing CTLs
in resolving acute hepatitis continued to increase at a time
when the ALT was decreasing and the HCV RNA had be-
come negative.
Phenotypic Characterization of the Antiviral CD81 Lympho-
cyte Response. The above studies provide a functional
analysis of the CTL response in terms of IFN-g produc-
tion, but do not assess for the presence of CTLs that may
be unable to mediate this specific effector function. The
use of peptide–HLA tetramers to directly visualize antigen-
specific CD8 cells by flow cytometry allows a more precise
quantification of the full complement of antigen-specific
cells. The HLA-A2–restricted CTL response was studied
Figure 1. Cytotoxic activity of HCV-specific clones derived in acute
infection. CTL clones from subject 1 (week 4) were expanded on recom-
binant HCV-vaccinia vector–infected B-LCLs and tested on truncated
peptides to determine their fine-specificity (A–H). Autologous 51Cr-
labeled B-LCLs were pulsed with the designated HCV peptide at the
concentrations shown, and percent specific lysis was determined at a con-
stant E/T ratio of 10:1. LMax, maximal percent specific lysis; SD50, con-
centration of optimal peptide (ng/ml) at which 50% of maximal lysis was
observed.1504 Analysis of Successful Immune Response in HCV Infection
in subject 1 using such tetrameric complexes to accurately
define the dynamics and phenotype of these populations.
Fluorescently labeled tetramers specific for four HLA-A2–
restricted epitopes (NS3 1073–1081, NS3 1406–1415,
NS4B 1807–1816, and NS5B 2594–2602) were used to
stain antigen-specific CD81 lymphocytes in PBMCs (Fig.
3 A). PBMCs were also stained for the presence of the ac-
tivation markers CD38, MHC class II, and CD69, as well
as the chemokine receptor CCR5. A very strong CD81
lymphocyte response was observed directed against the
epitope NS5B 2594, comprising 7.40% of circulating
CD81 lymphocytes at the first time point when the patient
was jaundiced (Fig. 3, A and B). These high levels of tet-
ramer-positive cells, which expressed the activation mark-
ers CD38 and HLA class II, occurred at the time of maxi-
mal ALT elevation, reflecting destruction of hepatocytes
(Fig. 3, B–D). The initial NS5B 2594–specific CD81 re-
sponse was also associated with the expression of high lev-
els of the chemokine receptor CCR5, which is mainly
found on Tc1 cells (37; Fig. 3 E). The frequency and acti-
vation status of NS5B 2594–specific CD81 lymphocytes
decreased parallel to the rapid drop of ALT. Although the
NS5B 2594–specific CD8 response persisted at a level of
z2% of CD8 cells, these cells no longer expressed elevated
levels of CD38 and HLA class II, as had been observed
during the peak of the response. The CD81 response
Figure 2. Antigen-specific IFN-g production of HCV-
specific T lymphocytes during resolution of acute HCV in-
fection. PBMCs from subject 1 were tested for HCV-spe-
cific IFN-g release in an ELISPOT assay at the time points
shown after presentation with acute HCV infection. (A)
Results from IFN-g ELISPOT assays using autologous
B-LCLs infected with the designated recombinant HCV-
vaccinia vectors as stimulator cells. (B) Results from IFN-g
ELISPOT assays using designated HCV peptides as stimu-
lators. The y-axis shows numbers of HCV-specific PBMCs
in 106 PBMCs producing IFN-g.
Figure 3. Tetramer analysis of PBMCs during and after acute disease. FACS® analysis data of PBMCs from subject 1 over time are shown: (A) percent-
age of CD81 lymphocytes that were tetramer-positive at each time point; (B) serum ALT levels and RT-PCR results; (C) percentage of total CD81
lymphocytes and tetramer-positive CD81 lymphocytes expressing CD38, (D) HLA class II molecules, and (E) CCR5 receptor. Percentage of CD38/
HLA class II expression on HCV-specific cells can only be shown where positive tetramer staining was obtained. No positive staining was obtained with
NS3 1406 or NS4B 1807 tetramers at any time point (not shown).1505 Lechner et al.
against the A2-restricted epitope NS3 1073 was subdomi-
nant at the time of initial analysis, with 1.1% of CD8 cells
reacting with this tetrameric complex. It also peaked later
than that against NS5B 2594 (maximum at week 10 5
2.35% of CD81 lymphocytes; Fig. 2 A) and remained
roughly at this level throughout follow-up. These cells
demonstrated lower levels of CD38 expression and only
slightly elevated HLA class II expression compared with
total CD81 lymphocytes, and peaked at a time when ALT
levels had already normalized (Fig. 3). No lymphocytes
stained with tetramers for the two HLA-A2–restricted
HCV epitopes NS3 1406 and NS4B 1807, consistent with
the lack of detection of these responses in the cloning as-
says. It should be noted that acute hepatitis was also associ-
ated to a lesser extent with increased expression of CD38,
HLA class II, and CCR5 on total CD81 lymphocytes (Fig.
3, C–E). These tetramer-negative CD381HLA class
II1CCR51 cells detected during clinical illness are likely to
include HCV-specific T cells recognizing epitopes other
than the HLA-A2–restricted one, e.g., those restricted by
HLA-A25, for which no tetramers were available. In addi-
tion, these cells may also represent activation of bystander
(non–HCV-specific) CD81 lymphocytes. This possibility is
suggested by the detection of EBV-specific cells expressing
elevated levels of CD38 and HLA class II at early time
points (Fig. 3, C and D). Expression of CD69 was not ele-
vated on tetramer-positive cells compared with total CD81
lymphocytes at any time point examined (data not shown).
IFN-g ELISPOT responses to both naturally processed
NS5B protein and peptide NS5B 2594 identified the peak
to be at week 10, whereas tetramer analysis showed that the
response to NS5B 2594 was highest at week 0 (Figs. 2 B
and 3 A). This result suggested that the early dominant
CTL response may have had impaired effector function at
the level of IFN-g production, as has been described in
murine chronic viral infections and in melanoma patients
(22, 28). To test whether the NS5B 2594–specific CD81
lymphocytes obtained at the time of acute infection showed
impaired IFN-g production in vitro, intracellular IFN-g
was measured in tetramer-positive cells after stimulation
with PMA and ionomycin. Whereas NS5B 2594–specific
cells obtained at weeks 10 and 32 readily produced IFN-g
after stimulation, IFN-g production was severely impaired
at week 0 compared with tetramer-negative cells (Fig. 4 A).
Consistent with this, in vitro peptide-induced upregulation
of CD69 was detectable at weeks 4 and 24 but not at week
0 (Fig. 4 B). These findings indicate that a high percentage
of the NS5B 2594–specific CTLs detected early in infec-
tion was unresponsive both to nonspecific and antigen-spe-
cific stimuli and would have been undetected or greatly un-
derestimated using IFN-g ELISPOT assays on their own.
Since unresponsiveness is a feature of cells exposed to
high levels of antigen (22, 26, 38), we looked for corrobo-
rative evidence that the NS5B 2954–specific cells had re-
cently been exposed to antigen. One measure of this is the
expression of tetramer-binding TCR and CD8 available at
Figure 4. Functional analysis of HCV-specific PBMCs. (A) Intracellular IFN-g staining. PBMCs from subject 1 were stimulated with PMA and iono-
mycin for 6 h or left unstimulated and subsequently stained with PE-labeled NS5B 2594 tetramers, PerCP-conjugated anti-CD8, and FITC-conjugated
anti–IFN-g or isotype control antibodies. Results from the gated CD81 lymphocytes are shown for different time points. The percentage of tetramer-
positive CD81 lymphocytes that express IFN-g is shown in each panel. (B) Peptide-induced upregulation of CD69. PBMCs were incubated with NS5B
2594 peptide (1 mM) for 4 h and stained with PE-labeled NS5B 2594 tetramers, FITC-conjugated CD69, and PerCP-conjugated CD8 antibodies. Re-
sults from the gated CD81 lymphocytes are shown for different time points. The percentages of tetramer-positive and tetramer-negative CD81 lympho-
cytes expressing CD69 are shown in each panel. (C) Cytolytic capacity of PBMCs from the first time point (week 0) was tested after 9 d of in vitro cul-
ture. PBMCs were prepulsed with NS5B 2594 peptide (10 mM) for 1 h, washed, and incubated for 3 d, after which 10% (vol/vol) IL-2 containing
Lymphocult-T (Biotest AG) was added. T2 cells (HLA-A21) were prepulsed with 1 mM cognate peptide (d) or no peptide (s) and used as targets in a
6-h 51Cr-release assay at E/T ratios shown.1506 Analysis of Successful Immune Response in HCV Infection
the cell surface, both of which are downregulated after
antigen exposure (39–42). Interestingly, at the first time
point evaluated, a percentage of NS5B 2594–specific cells
showed a reduced intensity of anti-CD8 antibody and tet-
ramer staining compared with later time points, a feature
that was not seen on NS3 2073– or EBV-specific lympho-
cytes (Fig. 5). These latter cells also showed lower levels of
CD38 and HLA class II expression consistent with a lower
level of activation. To investigate the proliferative and cy-
tolytic potential of these cells, PBMCs from week 0 were
placed in culture for 9 d with peptide and IL-2. After this
period, no expansion of the tetramer-positive population
was seen (total 5% of CD81 lymphocytes, data not shown),
nor was CD69 upregulated. However, these cells showed a
very marked lytic capacity (Fig. 4 C). These results indicate
that at the time of acute illness, the NS5B 2594–specific
cells were not able to produce IFN-g or respond to peptide
in culture, possibly due to recent encounter of antigen in
vivo; however, after cultivation they showed strong lytic
capacity. Due to a limited number of cells, we could not
test if the NS5B 2594–specific cells also exhibited lytic ac-
tivity when tested directly after isolation.
Antiviral T Helper Response in Acute Resolving HCV Infec-
tion. In subject 1, we were also able to study the antiviral
T helper response during the acute phase of the disease
(Fig. 6). IFN-g ELISPOT assays were performed on PB-
MCs, using recombinant proteins derived from HCV as
target antigens. Unlike IFN-g–secreting CTL responses,
antigen-specific T helper responses were maximal at the
first time point and remained high up to week 10, after
which the responses decreased z5–10-fold but still re-
mained readily detectable. The response was multispecific
at all times, a feature previously associated with clearance
after acute infection (23, 24, 43), and was calculated to
comprise z3% of CD41 lymphocytes at the time of maxi-
mal response. These results indicate that the peak magni-
tude of the detectable IFN-g T helper cell response pre-
ceded the peak magnitude of the IFN-g CTL response.
Analysis of HCV-specific T Lymphocyte Responses in Patients
with Recent Acute HCV. Two additional subjects were
identified with acute HCV infection, in whom blood for
immunologic analyses was first available a few weeks or
months after documented symptomatic illness. These two
HLA-A21 subjects had, as did subject 1, an acute self-limit-
ing illness, with jaundice and elevation of ALT after expo-
sure to HCV. Both subjects became HCV PCR–negative
before blood was taken for T cell analysis. In subject 2, the
first sample was obtained at week 4, and in subject 3, the
first sample was available at week 36. Using tetramer stain-
ing of PBMCs, antiviral CD81 responses were detected
against two (subject 2) or three (subject 3) of the three
tested HLA-A2–restricted epitopes, respectively. Re-
sponses to the HLA-A2–restricted epitope NS5B 2594
could not be determined because at the time of analysis this
epitope had not yet been characterized and therefore no
tetramers were available. In both subjects, switches in the
dominance of HCV-specific T cell responses occurred over
time, even weeks after the original illness and after clear-
ance of HCV from the blood by PCR and normalization
of ALT (Fig. 7). As in subject 1, the tetramer-positive pop-
ulations in subjects 2 and 3 persisted well beyond the clear-
ance of viremia. Interestingly, expansions of HCV-specific
lymphocytes after resolution of acute illness, despite their
magnitude (in subject 2 especially), did occur without ele-
vation of ALT, and the tetramer-positive cells showed low
expression of CD38 and HLA class II (,20% for CD38
and ,7% for HLA class II in both cases; not shown), simi-
lar to what was seen at later stages in subject 1. Potential re-
sponses to other peptides could not be tested because of the
lack of available cells for additional tetramer or ELISPOT
analysis. However, sufficient PBMCs from subject 3 were
available at week 93. We were able to demonstrate IFN-g
Figure 5. Relative expression of CD8 and tetramer-binding TCR over
time. To follow the course of TCR downregulation over time, the tet-
ramer-positive CD81 lymphocyte population is illustrated, and the per-
centages of gated cells that expressed a tetramer-low CD8low phenotype
are shown in each panel.
Figure 6. Analysis of T helper responses during and after acute infec-
tion. T helper responses of subject 1 to designated recombinant HCV
proteins were tested in an IFN-g ELISPOT assay. Time points are as for
Figs. 2 and 3. The y-axis shows numbers of HCV-specific PBMCs in 105
PBMCs producing IFN-g.1507 Lechner et al.
secretion in PMA-stimulated tetramer-positive CD81 lym-
phocytes as well as in peptide IFN-g ELISPOT assays at
this time point (peptides NS3 1073 and NS3 1406; data not
shown). In addition, a multispecific T helper response was
detected using recombinant proteins in an IFN-g
ELISPOT assay, with responses to NS3, NS4, and NS5
(not shown). This indicates that the secretory capacity of
the antiviral CTLs as well as T helper cells was preserved in
this subject, similar to the later time points of subject 1.
These results suggest that patients with resolving acute
HCV infection generate strong and multispecific T helper
cell as well as CTL responses that are maintained after reso-
lution of viremia and normalization of ALT.
Analysis of HCV-specific T Lymphocytes in Long-Term
HCV-seropositive Persons. 36 HLA-A21 persons who had
been HCV-seropositive for several years (see Materials and
Methods) were also screened using HLA-A2 tetramers.
These subjects were divided into two groups, depending on
the continued presence or not of virus in blood, as detected
by PCR. In those who remained PCR-positive, irrespec-
tive of ALT or treatment history, the percentage of HCV-
specific CD81 lymphocytes in peripheral blood was at or
below the limit of detection by tetramers (Fig. 8). This is
consistent with previous studies showing that CTL precur-
sor frequencies in chronic hepatitis C infection are rela-
tively low (4, 5). In those patients where HCV-specific cells
Figure 7. Tetramer analysis of PBMCs from two sub-
jects after resolution of acute hepatitis infection. Results of
tetramer stainings of PBMCs are illustrated as in Fig. 2.
Subjects 2 and 3 had developed acute disease, but the first
blood samples available were from time points when ALT
levels had already normalized and HCV RT-PCR was
negative. The expression on tetramer-positive CD81 lym-
phocytes of CD38 was ,20% and ,7% for HLA class II at
all stages (not shown). The NS5B 2594 tetramer was not
available at the time these specimens were analyzed.
Figure 8. Comparison of HCV-specific CD81 lymphocyte responses in subjects with acute HCV infection and in long-term HCV-seropositive sub-
jects. Tetramer staining was performed on PBMCs from subjects 1, 2, and 3 with documented primary acute HCV infection. Peak responses detected
during the first 20 mo after onset of disease are shown for each CTL epitope. 36 subjects who were long-term HCV-seropositive and either RNA PCR–
positive or –negative were also analyzed. As a comparison, HLA-A2–restricted EBV responses are shown for all patient groups. Results are shown as the
percentage of tetramer-positive cells among total CD81 lymphocytes. Filled symbols, subjects who were or became HCV RNA PCR–negative during
follow-up; open symbols, subjects who remained HCV RNA PCR-positive.1508 Analysis of Successful Immune Response in HCV Infection
could be detected (n 5 9/19), the average percentage of
tetramer-positive CD81 lymphocytes was 0.07 (Fig. 8). In
persons who were persistently antibody-positive but PCR-
negative, either spontaneously or after treatment, similarly
low levels of tetramer-positive CD81 lymphocytes were
seen (average 0.09%) compared with those observed during
or after acute infection, although in two cases, levels .0.2%
were seen. In one subject tested on two occasions .1 yr
apart, this population was maintained (not shown).
Compared with the patients who remained PCR-posi-
tive, there was overall a greater proportion of positive tet-
ramer responses observed in persons who cleared their
RNA (18/59 vs. 11/65 tests; P 5 0.07 by Fisher’s exact
test). There was also an excess of responses seen to the
NS5B 2594 epitope (4/8 vs. 0/10 persons; P 5 0.02 by
Fisher’s exact test). In the PCR-positive group, only one
subject (1/19) showed a response against more than one
tested epitope, whereas in the PCR-negative group 50% of
the responding persons had CTLs specific for more than
one tested epitope (P 5 0.04 by Fisher’s exact test). By
comparison, the percentage for EBV-specific cells in those
patients who had detectable EBV-specific CD81 T lym-
phocytes (n 5 22/36) was 0.32, thus higher in most patients
than the responses seen against HCV (P 5 0.047 by Wil-
coxon signed rank test).
In both PCR-positive and -negative persons, CD38 ex-
pression on HCV and EBV tetramer-positive CD81 lym-
phocytes was always ,15%, and HLA class II expression
was ,7% (data not shown). These results indicate that
CTL responses were more common in PCR-negative
subjects than in PCR-positive subjects, but these responses
were weak compared with patients who had recently re-
solved acute HCV infection and did not express activation
markers.
Discussion
There are two clearly defined outcomes after acute HCV
infection—on the one hand, clearance of the virus below
the level of detection by PCR, and on the other, viral per-
sistence associated with varying degrees of liver damage. It
is thought that the cellular immune response contributes to
control of the virus in the first instance, and potentially to
liver inflammation in chronic disease, but the details of
these associations have been difficult to disentangle. There
are at least four fundamental problems in doing so: the vi-
rus is highly variable, available immunologic assays have
lacked sensitivity, people typically present only years after
infection, and antiviral lymphocyte populations may be se-
questered in the liver (10, 44). Despite these problems, it is
important to understand the immune responses in early
HCV infection, as the events occurring during this period
may be crucial to the eventual outcome of this infection
(11, 43, 45, 46).
Fluctuations of Number and Function of T Cells in Acute Dis-
ease. A very broad antiviral T helper as well as CD81 T
lymphocyte response was detected in subject 1 from the
earliest time points. Using tetramers, maximal antiviral
CD81 lymphocyte frequency against one of the epitopes
(NS5B 2594) was determined to be 7.4% at the peak of
clinical illness when virus was still detectable (Fig. 3).
ELISPOT data suggest that the total frequency of antiviral
CTLs at early stages was even higher because the IFN-g re-
sponses found against other epitopes (for which no tetra-
mers were available) were as high as the response to NS5B
2594 (Fig. 2 B). This level of expansion of CTLs during
acute disease is of the same order of magnitude as that seen
during resolution of acute mononucleosis syndrome caused
by EBV, and higher than the levels found in chronic HIV
infection (33, 47).
A total of eight different epitopes were targeted simulta-
neously in subject 1 that had been characterized in the
greatest detail, and were presented by three different class I
alleles. In addition, these responses persisted for the dura-
tion of follow-up, despite clearance of viremia and resolu-
tion of hepatitis. The breadth of the response was thus
greater than that typically observed in chronic infection (8).
The quantitative data in the present study thus add signifi-
cantly to earlier studies of experimental acute HCV infec-
tion in chimpanzees, which showed variable recognition of
up to nine different epitopes in a single animal with resolv-
ing acute infection (25). Although the techniques used in
that study did not allow quantification of responses, persis-
tence of responses for up to 1.5 yr after infection was also
documented.
The availability of early samples as well as tetramers and
IFN-g ELISPOT assays allowed for the detection of a
dominant initial immune response in subject 1 that would
not have been appreciated with the more limited assays that
have typically been used to study HCV infection in hu-
mans and animals. Tetramer analysis revealed that the
NS5B 2594–specific CTLs expressed high levels of CD38
and HLA class II, representing an activated phenotype.
These cells also had reduced expression of TCR (as judged
by tetramer binding and anti-CD8 staining), suggesting re-
cent exposure to cognate antigen in vivo (39–41). Interest-
ingly, at this stage, the cells showed only limited capacity to
secrete IFN-g in vitro (in ELISPOT assays and after PMA
stimulation) and to upregulate CD69 after exposure to
peptide. The phenotype of these cells was unexpected, par-
ticularly as at later time points the cells adopted a more
conventional memory phenotype (CD38low and HLA class
IIlow, with capacity to secrete IFN-g and upregulate CD69
upon peptide stimulation).
The finding of subpopulations of CTLs with impaired
ability to secrete IFN-g in acute HCV infection has impor-
tant implications for HCV pathogenesis. We propose three
possible explanations for this phenomenon. First, the dom-
inant NS5B 2594–specific cell population at week 0 may
represent a subset of cells without IFN-g secreting capac-
ity. Despite this, NS5B 2594–specific CTLs detected at
later time points were capable of producing IFN-g. They
may have changed their cytokine secretion profile over
time, or alternatively, represent a different population of
cells with the same peptide specificity. Due to limitations in
cell numbers, we were unable to test exhaustively for dif-1509 Lechner et al.
ferential cytokine secretion at the first time point, but they
may theoretically have secreted IL-4 or IL-10 as has been
previously observed in HCV-specific CTL clones (2), or
only IL-2 but no IFN-g, a cytokine pattern found in naive
and a subset of memory CD41 lymphocytes (48). Second,
exposure to natural altered peptide ligands (APLs) emerg-
ing as the virus is suppressed may have altered the pheno-
type of these cells temporarily (49). Finally, the cells might
have undergone a process of antigen-induced partial deacti-
vation or exhaustion (22, 26, 38, 50). This may be particu-
larly facilitated by exposure to high concentrations of anti-
gen in the liver, without costimulation; it is possible that
CTLs detected in blood could theoretically represent those
cells leaving the liver after encountering antigen there, al-
though it has recently been shown that the majority of acti-
vated CD81 T cells entering the liver undergo apoptosis
within the liver environment (51). Although not com-
pletely exhausted, the NS5B 2594–specific cells showed a
temporarily dysfunctional phenotype, which we would de-
scribe as “stunned.” Their recovery may be due to the effi-
cient control of virus by the evolving broadly directed
CTL response, or through other mechanisms such as inter-
action with antigen-specific CD41 lymphocytes (22).
This study also illustrates the rapid emergence of T
helper responses in concert with CTL responses in early
disease. These IFN-g–producing T helper responses were
of broad specificity, and were of greatest magnitude at the
earliest time point sampled, in contrast to the CD8 IFN-g
responses. It is very likely these cells contributed to the res-
olution of disease, as suggested previously (23, 24, 43, 52).
The future development of HLA class II tetramers will be
important in dissecting the functional properties of these
cells and determining the relationship between the magni-
tude of antigen-specific CD4 responses and the ability to
proliferate and secrete cytokines.
Persistence and Fluctuation in CTL Responses after Acute
Disease. An unexpected feature of this study was the fluc-
tuation of populations of CTLs with different antigenic
specificities at a time when plasma viremia had been cleared
below the detection limit in blood and there was no further
evidence of biochemical hepatitis (Fig. 7). These expan-
sions of antiviral CTLs months after infection may be
caused by bystander activation by other immunogens, or
more likely may represent continued presentation of HCV
antigens to CTLs in lymphoid organs or the liver. There is
evidence for very low level presence of HCV RNA in the
liver even in some patients who clear the virus from blood,
and also in extrahepatic sites (53, 54).
The phenotype of CTLs in this phase after acute infec-
tion was also of interest. These populations of tetramer-
positive cells, which could reach frequencies of up to 4%
of CD81 lymphocytes, did not show an activated pheno-
type, which could explain why no concomitant rise in
ALT was observed. Alternatively, antigenic load was too
low in these subjects to cause detectable liver damage at
this stage. Low expression of CD38 and HLA class II on
antiviral cells is similarly found in patients who have suc-
cessfully cleared hepatitis B virus (13) or controlled acute
EBV infection (33). It is unlike HIV-infected patients, in
whom CD38 and HLA class II expression remains high on
lymphocytes in the chronic phase of uncontrolled infec-
tion but decreases after successful antiretroviral treatment
(47, 55–57).
In our group of persistently HCV antibody–positive sub-
jects, where initial exposure to HCV had taken place several
years previously, the levels of tetramer-positive CD81 lym-
phocytes were generally low and the few cells that were de-
tectable expressed low levels of CD38 and HLA class II,
even in those in whom virus persisted. Several potential
confounding factors may influence the magnitude of these
responses, including viral variation leading to escape from
immune recognition, reactivity to epitopes for which no
tetramers were available, or sequestration of activated effec-
tor cells in the liver, which could explain why the few cells
detected in the periphery expressed no activation markers.
The finding of low to undetectable levels of tetramer-posi-
tive cells in chronic infection was consistent with additional
studies using two HLA-B7 and two HLA-B8 tetramers
containing defined HCV epitopes (Lechner, F., and P. Kle-
nerman, unpublished results). Likewise, the HLA-A2, -B7,
and -B8 tetramers failed to detect HCV-specific CD81
lymphocytes derived from explanted livers in situations
where PBMCs were negative (58). Our results are consis-
tent with other studies of chronic infection, in that even in
situations where CTLs have been found by tetramers in the
nonacute situation, the levels have been in general low (typ-
ically ,0.1% of CD81 cells [10]). If the levels of antiviral
CTLs are truly low, particularly in the presence of virus, the
mechanisms leading to low CTL responses with a nonacti-
vated phenotype require further study. Apart from antigenic
variation leading to epitope loss or antagonism (59–61), or
loss of CD41 T helper responses (23, 24, 43), some long-
term immunomodulatory effect of the virus may also be in-
volved in chronic infection, which for example directly in-
terferes with lymphocyte activation or antigen presentation.
Implications for HCV Pathogenesis. The data presented
here indicate that strong and broadly directed CTL re-
sponses can be observed in persons with acute hepatitis
who go on to successfully control HCV infection. These
findings, coupled with the demonstration of a greater fre-
quency of detection of CTL responses in long-term sero-
positive persons who remain PCR-negative, provide a ra-
tionale to explore immunotherapy as an adjunctive therapy
in persons with chronic progressive HCV infection. In this
regard, it will be important to perform similar detailed lon-
gitudinal studies in persons who develop acute HCV hepa-
titis and do not go on to clear infection but sustain viral
replication.
It has been argued on the basis of animal models of HCV
and lymphocytic choriomeningitis virus infection that the
breadth of the CTL response may be important in main-
taining viral control (25, 62, 63). This study also demon-
strates a broadly directed CTL response in resolving infec-
tion, and emphasizes the fact that function as well as
number must be taken into account in drawing conclusions
about pathogenesis or protective roles of these cells.1510 Analysis of Successful Immune Response in HCV Infection
We speculate that there is a short period of time when
CTLs, acting in concert with CD41 lymphocytes and pos-
sibly NK cells, are effective in antiviral control—beyond
this, if virus is cleared, they may initially maintain a con-
ventional phenotype, but if virus persists their numbers and
effector function may decline (22). CTL activity is always a
two-edged sword, and it is likely that CTLs contribute to
hepatic inflammation and damage during acute disease
when they have appropriate number, phenotypic markers,
and lytic function. How they function or fail to function in
chronic disease remains an open question that demands fur-
ther study.
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